发明名称 |
Dry powder formulations of dNase I |
摘要 |
DNase I formulations for pulmonary administration and, more particularly, but not exclusively, a dry powder formulation comprising, as an active ingredient, human DNase I, methods, dry powder inhalation devices and systems for the therapeutic use thereof are provided. |
申请公布号 |
US9603907(B2) |
申请公布日期 |
2017.03.28 |
申请号 |
US201314375485 |
申请日期 |
2013.01.31 |
申请人 |
Protalix Ltd. |
发明人 |
Shaaltiel Yoseph;Hanania Uri;Kizhner Tali;Matiuhin Yulia;Fux Liat;Shulman Avidor |
分类号 |
A61K38/46;C12N9/22;C12N9/82;C12N15/82;A61K9/00;A61K38/47;A61K33/06;A61K45/06;A61K9/14;A61K33/14 |
主分类号 |
A61K38/46 |
代理机构 |
|
代理人 |
|
主权项 |
1. An inhalable dry powder formulation comprising a human DNase I protein and particles of a physiologically acceptable pharmacologically-inert solid carrier, wherein said human DNase I protein is a plant expressed recombinant human DNase I protein comprising an N-terminal Glycine residue at position 1 of said human DNase I protein. |
地址 |
Carmiel IL |